As the gross domestic product (GDP) growth rate in India nears 9%, diagnostic manufacturers are preparing to collect their share of the in vitro (IVD) diagnostics market, which, according to healthcare market research publisher Kalorama Information (New York, NY, USA), is expected to enjoy a 15% growth rate through 2014.

Kalorama's report has market projections, pricing comparisons, and profiles of major competitors in the industry. It covers routine chemistry, urine chemistry, hematology, coagulation, cytometry, immunochemistry, rapid testing, blood screening, and molecular testing.

According to Kalorama Information, companies such as), Dr. Lal Path Labs (Gurgaon, India), SRL Ranbaxy (Gurgaon, India), and Quest (Gurgaon, India) are building new laboratories, and frequently engage in partnerships with the public sector. This immense cycle of growth is leading to a shortage in the availability of reagents, as private and public sectors compete for supplies from a growing reagent rental program.

"It's not surprising to see a shortage of reagents in the market,” noted Bruce Carlson, publisher of Kalorama Information. "With the considerable growth in India, there is likely to be a shortage of some medical supplies at various times.”

Metropolitan growth in India has encouraged India's rural citizens to relocate new urban centers, increasing prosperity, insurance availability, and the number of individuals willing to pay for healthcare. The Kalorama report also notes government activity, which promotes medical tourism thus attracting foreign patients interested in paying less for similar healthcare services offered in the west.

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services.

Related Links:
Kalorama Information
Dr. Lal Path Labs
SRL Ranbaxy
Quest Diagnostics India